Shares in Novo Nordisk and Eli Lilly have been under pressure after a study emerged suggesting that people taking a GLP-1 agonist had an elevated risk of a rare but serious eye condition.The study published in the journal JAMA Ophthalmology focused on semaglutide, the GLP-1 agonist in Novo Nordisk’s diabetes therapy Ozempic and obesity treatment Wegovy, which has become sought-after for its weight-loss properties.
